As of 2026-05-26, the EV/EBITDA ratio of Hybio Pharmaceutical Co Ltd (300199.SZ) is 129.50. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. 300199.SZ's latest enterprise value is 24,259.50 mil CNY. 300199.SZ's TTM EBITDA according to its financial statements is 187.33 mil CNY. Dividing these 2 quantities gives us the above 300199.SZ EV/EBITDA ratio.
| Range | Selected | |
| Trailing P/E multiples | 18.5x - 19.7x | 19.2x |
| Forward P/E multiples | 8.9x - 11.6x | 10.1x |
| Fair Price | 1.87 - 4.56 | 2.87 |
| Upside | -92.7% - -82.0% | -88.7% |
| Date | EV/EBITDA |
| 2026-05-22 | 125.44 |
| 2026-05-21 | 116.96 |
| 2026-05-20 | 120.49 |
| 2026-05-19 | 122.47 |
| 2026-05-18 | 124.31 |
| 2026-05-15 | 119.83 |
| 2026-05-14 | 115.97 |
| 2026-05-13 | 117.99 |
| 2026-05-12 | 104.56 |
| 2026-05-11 | 106.40 |
| 2026-05-08 | 106.07 |
| 2026-05-07 | 108.61 |
| 2026-05-06 | 108.28 |
| 2026-04-30 | 107.48 |
| 2026-04-29 | 108.61 |
| 2026-04-28 | 113.89 |
| 2026-04-27 | 115.26 |
| 2026-04-24 | 112.20 |
| 2026-04-23 | 113.66 |
| 2026-04-22 | 116.11 |
| 2026-04-21 | 112.53 |
| 2026-04-20 | 111.96 |
| 2026-04-17 | 109.89 |
| 2026-04-16 | 108.47 |
| 2026-04-15 | 108.42 |
| 2026-04-14 | 109.70 |
| 2026-04-13 | 108.61 |
| 2026-04-10 | 111.21 |
| 2026-04-09 | 107.72 |
| 2026-04-08 | 107.62 |
| 2026-04-07 | 101.63 |
| 2026-04-03 | 101.26 |
| 2026-04-02 | 104.75 |
| 2026-04-01 | 104.70 |
| 2026-03-31 | 98.71 |
| 2026-03-30 | 100.17 |
| 2026-03-27 | 98.33 |
| 2026-03-26 | 93.81 |
| 2026-03-25 | 93.71 |
| 2026-03-24 | 94.28 |
| 2026-03-23 | 91.50 |
| 2026-03-20 | 94.85 |
| 2026-03-19 | 99.09 |
| 2026-03-18 | 97.06 |
| 2026-03-17 | 95.79 |
| 2026-03-16 | 94.80 |
| 2026-03-13 | 93.10 |
| 2026-03-12 | 93.34 |
| 2026-03-11 | 94.89 |
| 2026-03-10 | 93.90 |